全文获取类型
收费全文 | 747篇 |
免费 | 345篇 |
专业分类
口腔科学 | 1篇 |
临床医学 | 6篇 |
内科学 | 1077篇 |
特种医学 | 2篇 |
外科学 | 4篇 |
预防医学 | 1篇 |
药学 | 1篇 |
出版年
2023年 | 29篇 |
2021年 | 53篇 |
2020年 | 2篇 |
2018年 | 38篇 |
2017年 | 84篇 |
2016年 | 78篇 |
2015年 | 89篇 |
2014年 | 79篇 |
2013年 | 127篇 |
2012年 | 107篇 |
2011年 | 94篇 |
2010年 | 110篇 |
2009年 | 98篇 |
2008年 | 78篇 |
2007年 | 14篇 |
2006年 | 2篇 |
2005年 | 1篇 |
2004年 | 1篇 |
2000年 | 1篇 |
1999年 | 1篇 |
1998年 | 4篇 |
1995年 | 1篇 |
1991年 | 1篇 |
排序方式: 共有1092条查询结果,搜索用时 15 毫秒
21.
22.
23.
24.
25.
Jyunya Matsumi MD Shigeru Saito MD FACC FSCAI 《Catheterization and cardiovascular interventions》2008,71(6):810-814
After the introduction of the retrograde approach in percutaneous coronary intervention for chronic total occlusion (CTO), different kinds of strategies and techniques have been developed in order to achieve final success. However, it has not been fully demonstrated whether these strategies and techniques can really improve the final result. We observed one case, for which the initial attempt of the retrograde approach for a CTO lesion was unsuccessful despite the successful approach of a retrograde guidewire to the lesion, and with the second retrograde approach 3 years later being eventually successful by using various kinds of strategies and techniques. This case clearly demonstrates how the final success through the retrograde approach can be achieved by using a combination of the improved strategies and techniques for CTO lesions. © 2008 Wiley‐Liss, Inc. 相似文献
26.
Zahid Amin MD FSCAI Ziyad M. Hijazi MD FSCAI John L. Bass MD John P. Cheatham MD FSCAI William Hellenbrand MD FSCAI Charles S. Kleinman MD FSCAI 《Catheterization and cardiovascular interventions》2008,72(1):74-79
Objectives: To evaluate all complications that occurred during or after cardiac catheterizations for Amplatzer PFO device closure of patent foramen ovale (PFO), determine the cause of the complications and recommend techniques to minimize complications in the future. Background: Rare complications were reported to the manufacturer of the Amplatzer PFO occluder since the introduction of the device. Methods: A panel of independent physicians reviewed all complications reported to the manufacturer to determine whether the complication was related to the device or related to the cardiac catheterization procedure. Demographic data, echocardiograms, operative reports, and time to occurrence of complications were reviewed. Results: A total of 11 events were reported. Only two patients had device related complications (erosion), an incidence of 0.018%. Two patients were found to have additional atrial septal defect after PFO closure. Two patients were thought to have an inflammatory reaction without any serious sequelae. Five complications were related to the cardiac catheterization procedure (atrial appendage perforation). Conclusions: Device related complications after Amplatzer PFO occluder placement are extremely rare. Cardiac catheterization related complications appear to be the most common cause of the hemodynamic compromise. Careful manipulation of catheters and wires, recognition of the location of the catheter by fluoroscopy and echocardiography will decrease the risk of such complications. © 2008 Wiley‐Liss, Inc. 相似文献
27.
Riccardo Colantonio MD Azeem Latib MB BCh Giuseppe M. Sangiorgi MD FESC FSCAI 《Catheterization and cardiovascular interventions》2008,72(5):710-713
In this case report, we describe the use of coronary techniques and devices in the treatment of a complex popliteal artery bifurcation. In particular, we demonstrate that the Venture? wire control catheter is a useful tool not only in coronary lesions but also in wiring angulated peripheral lesions. © 2008 Wiley‐Liss, Inc. 相似文献
28.
29.
Jorge A. Belardi MD FACC FSCAI Mariano Albertal MD PHD FACC 《Catheterization and cardiovascular interventions》2016,87(3):532-533
- Acute kidney injury (AKI) is frequently observed immediately after transcatheter aortic valve implantation (TAVI).
- Both classifications, the RIFLE (the Risk, Injury, Failure, Loss, and End‐stage Kidney) and the KDIGO (Kidney Disease: Improving Global Outcomes) from the VARC‐2 (Valve Academic Research Consortium‐2) are fairly interchangeable and performed well as clinical predictors of all‐cause mortality.
- Patients with baseline reduced glomerular filtration rate (GFR) or known atherosclerotic arterial disease are at increased risk of AKI.
30.